Inhibition of VEGFR and other tyrosine kinase receptors with pazopanib has been shown to improve PFS relative to placebo in patients with STS [5] and also alter signaling through PI3K/Akt and MAPK pathways [21,22]. This evidence concerns the gene KDR and telomere syndrome.